Literature DB >> 1705351

Bleomycin: a pharmacologic tool in the study of the pathogenesis of interstitial pulmonary fibrosis.

J S Lazo1, D G Hoyt, S M Sebti, B R Pitt.   

Abstract

Bleomycin is a unique DNA-interactive antitumor agent that has become a popular tool in studies of the pathogenesis of interstitial pulmonary fibrosis. The biochemical and morphological changes seen in the lungs of many species after bleomycin simulate those seen in humans. The availability of these animal models of interstitial pulmonary fibrosis also provides the opportunity to investigate novel pharmacological approaches to preventing this disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1705351     DOI: 10.1016/0163-7258(90)90061-6

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  17 in total

Review 1.  Animal models for scleroderma: an update.

Authors:  Yan Zhang; Anita C Gilliam
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

2.  miR-29 is a major regulator of genes associated with pulmonary fibrosis.

Authors:  Leah Cushing; Ping Ping Kuang; Jun Qian; Fengzhi Shao; Junjie Wu; Frederic Little; Victor J Thannickal; Wellington V Cardoso; Jining Lü
Journal:  Am J Respir Cell Mol Biol       Date:  2010-10-22       Impact factor: 6.914

3.  Prevention of bleomycin-induced pulmonary fibrosis after adenovirus-mediated transfer of the bacterial bleomycin resistance gene.

Authors:  P L Tran; J Weinbach; P Opolon; G Linares-Cruz; J P Reynes; A Grégoire; E Kremer; H Durand; M Perricaudet
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

4.  A novel method for accurate collagen and biochemical assessment of pulmonary tissue utilizing one animal.

Authors:  Corrine R Kliment; Judson M Englert; Lauren P Crum; Tim D Oury
Journal:  Int J Clin Exp Pathol       Date:  2011-04-12

5.  Region-specific role for Pten in maintenance of epithelial phenotype and integrity.

Authors:  Per Flodby; Janice M Liebler; Mitsuhiro Sunohara; Dan R Castillo; Alicia M McConnell; Manda S Krishnaveni; Agnes Banfalvi; Min Li; Barry Stripp; Beiyun Zhou; Edward D Crandall; Parviz Minoo; Zea Borok
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-11-18       Impact factor: 5.464

6.  Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux.

Authors:  Kui Wang; Tao Zhang; Yunlong Lei; Xuefeng Li; Jingwen Jiang; Jiang Lan; Yuan Liu; Haining Chen; Wei Gao; Na Xie; Qiang Chen; Xiaofeng Zhu; Xiang Liu; Ke Xie; Yong Peng; Edouard C Nice; Min Wu; Canhua Huang; Yuquan Wei
Journal:  Autophagy       Date:  2018-01-29       Impact factor: 16.016

7.  Increased and prolonged pulmonary fibrosis in surfactant protein C-deficient mice following intratracheal bleomycin.

Authors:  William E Lawson; Vasiliy V Polosukhin; Georgios T Stathopoulos; Ornella Zoia; Wei Han; Kirk B Lane; Bo Li; Edwin F Donnelly; George E Holburn; Kenneth G Lewis; Robert D Collins; William M Hull; Stephan W Glasser; Jeffrey A Whitsett; Timothy S Blackwell
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

8.  Focal adhesion kinase (FAK)-related non-kinase inhibits myofibroblast differentiation through differential MAPK activation in a FAK-dependent manner.

Authors:  Qiang Ding; Candece L Gladson; Hongju Wu; Haurko Hayasaka; Mitchell A Olman
Journal:  J Biol Chem       Date:  2008-07-31       Impact factor: 5.157

9.  Respiratory reovirus 1/L induction of intraluminal fibrosis, a model of bronchiolitis obliterans organizing pneumonia, is dependent on T lymphocytes.

Authors:  Elizabeth I Majeski; Manjeet K Paintlia; Andrea D Lopez; Russell A Harley; Steven D London; Lucille London
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

10.  Rat alveolar myofibroblasts acquire alpha-smooth muscle actin expression during bleomycin-induced pulmonary fibrosis.

Authors:  S L Vyalov; G Gabbiani; Y Kapanci
Journal:  Am J Pathol       Date:  1993-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.